MétaCan
Menu
Back to cohort
Record W2755591022 · doi:10.1002/mds.27122

Design optimization for clinical trials in early‐stage manifest Huntington's disease

2017· article· en· W2755591022 on OpenAlexaff
Chris Frost, Amy Mulick, Rachael I. Scahill, Gail Owen, Elizabeth Aylward, Blair R. Leavitt, Alexandra Dürr, Raymund A.C. Roos, Beth Borowsky, Julie C. Stout, Ralf Reilmann, Douglas R. Langbehn, Sarah J. Tabrizi, Cristina Sampaio

Bibliographic record

VenueMovement Disorders · 2017
Typearticle
Languageen
FieldNeuroscience
TopicGenetic Neurodegenerative Diseases
Canadian institutionsUniversity of British Columbia
FundersWellcome TrustMedical Research CouncilUniversity College London Hospitals NHS Foundation TrustNational Institute for Health and Care ResearchCHDI Foundation
KeywordsSample size determinationCovariateObservational studyClinical trialRandomizationRandomized controlled trialInterimOutcome (game theory)Interim analysisResearch designGeneralizability theoryMedicineStatisticsPsychologyPhysical therapyInternal medicineMathematics

Abstract

fetched live from OpenAlex

OBJECTIVES: The purpose of this study was to inform the design of randomized clinical trials in early-stage manifest Huntington's disease through analysis of longitudinal data from TRACK-Huntington's Disease (TRACK-HD), a multicenter observational study. METHODS: We compute sample sizes required for trials with candidate clinical, functional, and imaging outcomes, whose aims are to reduce rates of change. The calculations use a 2-stage approach: first using linear mixed models to estimate mean rates of change and components of variability from TRACK-HD data and second using these to predict sample sizes for a range of trial designs. RESULTS: For each outcome, the primary drivers of the required sample size were the anticipated treatment effect and the duration of treatment. Extending durations from 1 to 2 years yielded large sample size reductions. Including interim visits and incorporating stratified randomization on predictors of outcome together with covariate adjustment gave more modest, but nontrivial, benefits. Caudate atrophy, expressed as a percentage of its baseline, was the outcome that gave smallest required sample sizes. DISCUSSION: Here we consider potential required sample sizes for clinical trials estimated from naturalistic observation of longitudinal change. Choice among outcome measures for a trial must additionally consider their relevance to patients and the expected effect of the treatment under study. For all outcomes considered, our results provide compelling arguments for 2-year trials, and we also demonstrate the benefits of incorporating stratified randomization coupled with covariate adjustment, particularly for trials with caudate atrophy as the primary outcome. The benefits of enrichment are more debatable, with statistical benefits offset by potential recruitment difficulties and reduced generalizability. © 2017 International Parkinson and Movement Disorder Society.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.225
metaresearch head score (Gemma)0.362
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.225
Threshold uncertainty score0.956

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.2250.362
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.004
Bibliometrics0.0020.001
Science and technology studies0.0010.002
Scholarly communication0.0030.003
Open science0.0020.003
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.218
GPT teacher head0.423
Teacher spread0.204 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designTheoretical or conceptual
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueMovement DisordersSame topicGenetic Neurodegenerative DiseasesFrench-language works237,207